Literature DB >> 26722276

Cyclin G2: A novel independent prognostic marker in pancreatic cancer.

Shinichiro Hasegawa1, Hiroaki Nagano2, Masamitsu Konno3, Hidetoshi Eguchi2, Akira Tomokuni2, Yoshito Tomimaru2, Hiroshi Wada2, Naoki Hama2, Koichi Kawamoto2, Shogo Kobayashi2, Shigeru Marubashi2, Naohiro Nishida3, Jun Koseki4, Noriko Gotoh5, Shouichi Ohno6, Norikazu Yabuta6, Hiroshi Nojima6, Masaki Mori2, Yuichiro Doki2, Hideshi Ishii7.   

Abstract

Unlike other cyclins that positively regulate the cell cycle, cyclin G2 (CCNG2) regulates cell proliferation as a tumor suppressor gene. A decreased CCNG2 expression serves as a marker for poor prognosis in several types of cancer. The aim of the present study was to clarify the correlation of CCNG2 expression with overall survival and histopathological factors in pancreatic cancer patients. This retrospective analysis included data from 36 consecutive patients who underwent complete surgical resection for pancreatic cancer and did not undergo any preoperative therapies. The association between prognoses and the expression of CCNG2 was assessed using immunohistochemical staining. Multivariate analysis identified that the expression of CCNG2 is an independent prognostic factor. In addition, the Kaplan-Meier curve for overall survival revealed that decreased expression of CCNG2 was a consistent indicator of poor prognosis in pancreatic cancer patients (P=0.0198). A decreased CCNG2 expression significantly correlated with venous invasion in tumor specimens and the tumor invasion depth. In conclusion, CCNG2 expression inversely reflected cancer progression and may be a novel, independent prognostic marker in pancreatic cancer.

Entities:  

Keywords:  cyclin G2; immunohistochemical staining; overall survival; pancreatic cancer

Year:  2015        PMID: 26722276      PMCID: PMC4665725          DOI: 10.3892/ol.2015.3667

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

1.  Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.

Authors:  Hiroaki Ohigashi; Osamu Ishikawa; Hidetoshi Eguchi; Hidenori Takahashi; Kunihito Gotoh; Terumasa Yamada; Masahiko Yano; Akihiko Nakaizumi; Hiroyuki Uehara; Yoshihiko Tomita; Kinji Nishiyama
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

2.  Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine.

Authors:  Zhenyu Zhao; Yu Liu; Hua He; Xin Chen; Juxiang Chen; Yi-Cheng Lu
Journal:  Brain Res Bull       Date:  2011-07-22       Impact factor: 4.077

3.  Cyclin G2 dysregulation in human oral cancer.

Authors:  Yong Kim; Satoru Shintani; Yohko Kohno; Rong Zhang; David T Wong
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

4.  CCNG2 suppressor biological effects on thyroid cancer cell through promotion of CDK2 degradation.

Authors:  Wei-Juan Li; Ge-Ling Liu; Fang Yu; Xiu-Xiu Xiang; Yi-Fang Lu; Hong-Zhen Xiao; Yan-Ping Shi
Journal:  Asian Pac J Cancer Prev       Date:  2013

5.  Changes in the expression of cyclin G2 in esophageal cancer cell and its significance.

Authors:  J Q Chen; C J Liu; H X Wen; C L Shi; H S Zhang; M Li; G G Sun
Journal:  Tumour Biol       Date:  2013-12-03

6.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

Authors:  Douglas B Evans; Gauri R Varadhachary; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Huamin Wang; Karen R Cleary; Gregg A Staerkel; Chusilp Charnsangavej; Elizabeth A Lano; Linus Ho; Renato Lenzi; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

7.  Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2.

Authors:  Takashi Kasukabe; Junko Okabe-Kado; Yoshio Honma
Journal:  Cancer Sci       Date:  2008-08       Impact factor: 6.716

8.  CCNG2 expression is downregulated in colorectal carcinoma and its clinical significance.

Authors:  G G Sun; J Zhang; W N Hu
Journal:  Tumour Biol       Date:  2013-12-03

9.  Decreased expression of CCNG2 is significantly linked to the malignant transformation of gastric carcinoma.

Authors:  G G Sun; W N Hu; D W Cui; J Zhang
Journal:  Tumour Biol       Date:  2013-11-19

10.  Change in expression of cyclin G2 in kidney cancer cell and its significance.

Authors:  D W Cui; G G Sun; Y J Cheng
Journal:  Tumour Biol       Date:  2013-11-23
View more
  13 in total

1.  Gut microbiome disruption altered the biotransformation and liver toxicity of arsenic in mice.

Authors:  Liang Chi; Jingchuan Xue; Pengcheng Tu; Yunjia Lai; Hongyu Ru; Kun Lu
Journal:  Arch Toxicol       Date:  2018-10-24       Impact factor: 5.153

2.  Comprehensive phenotypic analysis of knockout mice deficient in cyclin G1 and cyclin G2.

Authors:  Shouichi Ohno; Jun-Ichiro Ikeda; Yoko Naito; Daisuke Okuzaki; Towa Sasakura; Kohshiro Fukushima; Yukihiro Nishikawa; Kaori Ota; Yorika Kato; Mian Wang; Kosuke Torigata; Takashi Kasama; Toshihiro Uchihashi; Daisaku Miura; Norikazu Yabuta; Eiichi Morii; Hiroshi Nojima
Journal:  Sci Rep       Date:  2016-12-16       Impact factor: 4.379

3.  Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells.

Authors:  Verónica Cánovas; Yolanda Puñal; Valentina Maggio; Enric Redondo; Mercedes Marín; Begoña Mellado; Mireia Olivan; Matilde Lleonart; Jacques Planas; Juan Morote; Rosanna Paciucci
Journal:  Oncotarget       Date:  2017-07-22

4.  miR-1246 Targets CCNG2 to Enhance Cancer Stemness and Chemoresistance in Oral Carcinomas.

Authors:  Shih-Shen Lin; Chih-Yu Peng; Yi-Wen Liao; Ming-Yung Chou; Pei-Ling Hsieh; Cheng-Chia Yu
Journal:  Cancers (Basel)       Date:  2018-08-16       Impact factor: 6.639

5.  Several genes involved in the JAK-STAT pathway may act as prognostic markers in pancreatic cancer identified by microarray data analysis.

Authors:  Chun Pang; Yuan Gu; Yuechao Ding; Chao Ma; Wei Yv; Qian Wang; Bo Meng
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

6.  LncRNA GAS8-AS1 suppresses papillary thyroid carcinoma cell growth through the miR-135b-5p/CCND2 axis.

Authors:  NingHeng Chen; DeTao Yin; Bing Lun; XueLi Guo
Journal:  Biosci Rep       Date:  2019-01-11       Impact factor: 3.840

7.  Cyclin G2 Inhibits the Warburg Effect and Tumour Progression by Suppressing LDHA Phosphorylation in Glioma.

Authors:  Sen Li; Jinlan Gao; Xinbin Zhuang; Chenyang Zhao; Xiaoyu Hou; Xuesha Xing; Chen Chen; Qi Liu; Shuang Liu; Yang Luo
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

8.  Knockdown of long non-coding RNA PVT1 inhibits the proliferation of Raji cells through cell cycle regulation.

Authors:  Chanli Zheng; Yu Xiao; Yangqiu Li; Dongmei He
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

9.  CCNG2 Overexpression Mediated by AKT Inhibits Tumor Cell Proliferation in Human Astrocytoma Cells.

Authors:  Danfeng Zhang; Chunhui Wang; Zhenxing Li; Yiming Li; Dawei Dai; Kaiwei Han; Liquan Lv; Yicheng Lu; Lijun Hou; Junyu Wang
Journal:  Front Neurol       Date:  2018-04-18       Impact factor: 4.003

10.  Cyclin G2 regulates canonical Wnt signalling via interaction with Dapper1 to attenuate tubulointerstitial fibrosis in diabetic nephropathy.

Authors:  Chenyang Zhao; Jinlan Gao; Sen Li; Qi Liu; Xiaoyu Hou; Xuesha Xing; Danning Wang; Manni Sun; Shusen Wang; Yang Luo
Journal:  J Cell Mol Med       Date:  2020-01-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.